Affiliation:
1. Advanced Centre for Treatment Research and Education in Cancer, Kharghar Navi Mumbai Maharashtra India
2. School of Physical Sciences Jawaharlal Nehru University New Delhi India
3. Department of Microbiology, SSN College University of Delhi Delhi India
4. Department of Biotechnology Mizoram University Mizoram India
5. College of Veterinary Science Assam Agricultural University, Khanapara Guwahati Assam India
6. Homi Bhabha National Institute Training School Complex, Anushaktinagar Mumbai India
Abstract
AbstractCheckpoint kinases Chk1, Chk2, Wee1 are playing a key role in DNA damage response and genomic integrity. Cancer‐associated mutations identified in human Chk1, Chk2, and Wee1 were retrieved to understand the function associated with the mutation and also alterations in the folding pattern. Therefore, an attempt has been made to identify deleterious effect of variants using in silico and structure‐based approach. Variants of uncertain significance for Chk1, Chk2, and Wee1 were retrieved from different databases and four prediction servers were employed to predict pathogenicity of mutations. Further, Interpro, I‐Mutant 3.0, Consurf, TM‐align, and have (y)our protein explained were used for comprehensive study of the deleterious effects of variants. The sequences of Chk1, Chk2, and Wee1 were analyzed using Clustal Omega, and the three‐dimensional structures of the proteins were aligned using TM‐align. The molecular dynamics simulations were performed to explore the differences in folding pattern between Chk1, Chk2, Wee1 wild‐type, and mutant protein and also to evaluate the structural integrity. Thirty‐six variants in Chk1, 250 Variants in Chk2, and 29 in Wee1 were categorized as pathogenic using in silico prediction tools. Furthermore, 25 mutations in Chk1, 189 in Chk2, and 14 in Wee1 were highly conserved, possessing deleterious effect and also influencing the protein structure and function. These identified mutations may provide underlying genetic intricacies to serve as potential targets for therapeutic inventions and clinical management.
Funder
Department of Biotechnology, Ministry of Science and Technology, India
Subject
Cell Biology,Molecular Biology,Biochemistry